PARP inhibitorFDA-approvedSecond-line
Rucaparib
How it works
Blocks an enzyme that helps repair DNA damage, making cancer cells more susceptible to death.
Cancer types
Prostate Cancer— Patients with BRCA1 or BRCA2 mutations
Ovarian Cancer— BRCA-mutated
Efficacy
Rucaparib has been shown to improve progression-free survival in patients with BRCA1/2-mutated ovarian cancer, with a median progression-free survival of approximately 10.8 months.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Rucaparib's Effectiveness in Recurrent Ovarian Cancer | Ovarian Cancer | meta-analysis | The pooled objective response rate (ORR) was 0.331 (95% CI, 0.221-0.449; I2 = 92.4%). | Source → |
| PARP Inhibitor Resistance in Pancreatic Cancer | Pancreatic Cancer | observational | Reversions were significantly associated with rapid resistance to PARPi treatment (median PFS, 3.7 vs. 12.5 months; P = 0.001) and poor overall survival (median OS, 6.2 vs. 23.0 months; P < 0.0001). | Source → |
| Combining Two Drugs to Treat Advanced Prostate Cancer | Prostate Cancer | phase-1/2 | The PSA response rate was 26% (9/35), and the objective response rate per Response Criteria in Solid Tumors (RECIST) 1.1 was 10% (2/21). | Source → |
| Mathematical Model Predicts Rucaparib Efficacy in Ovarian Cancer | Ovarian Cancer | phase-2 | The KELIM-PARP score was associated with subsequent complete/partial radiological responses (odds-ratio = 2.81, 95% CI 1.86-4.52), and PFS (KELIM-PARP: hazard-ratio = 0.67, 95% CI 0.50-0.91). | Source → |
| Rucaparib May Help Some Ovarian Cancer Patients Live Longer Without Progression | Ovarian Cancer | phase-3 | Rucaparib treatment was significantly associated with exceptional benefit compared with placebo: 79/375 (21.1%) vs 4/189 (2.1%), respectively (p < 0.0001). | Source → |
| Rucaparib Works for Some Men with Advanced Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Rucaparib and Nivolumab Tested as Maintenance Treatment for Ovarian Cancer | Ovarian Cancer | phase-3 | — | Source → |
| Rucaparib's Effect on Ovarian Cancer Cells with BRCA2 Mutations | Ovarian Cancer | lab-study | — | Source → |
| Rucaparib Response Predicted by Genetic Mutations in Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Combining Rucaparib and Bevacizumab in Ovarian Cancer Treatment | Ovarian Cancer | phase-1 | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.